Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2017-10-04 Investor Presentation
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release dated October 4, 2017, announcing that the company, Lysogene, will be participating in several upcoming investor conferences in October and November 2017. It details the dates, times, and locations of these events where company presentations will occur. This type of announcement, which informs investors about scheduled meetings or presentations at industry events, aligns best with the 'Investor Presentation' (IP) category if it were the presentation itself, but since it is an *announcement* of future participation in investor events, it fits the general scope of investor relations communication. However, none of the codes perfectly capture 'Announcement of Investor Conference Participation'. Given the options, this document is primarily about informing investors of upcoming opportunities to hear company updates, which is closely related to Investor Presentations (IP) or general Regulatory Filings (RNS). Since it is not a formal regulatory filing like a 10-K or an ER, and it is not a presentation itself, the most appropriate general category for an announcement related to investor engagement that doesn't fit a more specific category (like DIV, DIRS, or MANG) is RNS. Alternatively, because the content is entirely focused on upcoming investor meetings where presentations will be given, IP might be considered, but IP is defined as the presentation itself. Following the 'MENU VS MEAL' rule, this is an announcement, not the core report/presentation. Therefore, RNS (Regulatory Filings / Miscellaneous Announcement) is the safest fallback, although RPA (Report Publication Announcement) is also plausible if we consider the conference schedule as a type of 'report' publication schedule. Given the context of investor events, RNS is the standard catch-all for non-standard announcements.
2017-10-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated October 4, 2017, announcing the company's upcoming participation in several investor conferences scheduled for October and November 2017 (Chardan Gene Therapy Conference, Jefferies Gene Editing & Gene Therapy Summit, Jefferies 2017 London Healthcare Conference). This type of announcement, which details future investor engagement events rather than releasing financial results or official statutory reports, is best classified as an Investor Presentation (IP) material announcement or, more broadly, a communication aimed at investors about future events. However, since the document itself is an announcement *about* attending investor events, and not the presentation slides themselves, it fits best under the category of general investor communication. Given the options, this is a specific announcement regarding investor relations activities. While it is not a formal regulatory filing (RNS) or a specific report, it is directly related to investor engagement. The closest fit among the provided options for an announcement detailing future investor meetings/conferences is often grouped with Investor Presentations (IP) or sometimes treated as a general Regulatory Filing (RNS) if no better fit exists. Since it details specific events where the company will present information to investors, 'Investor Presentation' (IP) is a strong candidate, although it is an announcement *of* participation. Given the context of financial reporting categories, announcements about future investor events are often categorized as Investor Presentation (IP) or Report Publication Announcement (RPA) if it were announcing the release of a document. Since it is announcing participation in external conferences, and not the release of an internal report, and it is a specific communication to the market, I will classify it as a general Regulatory Filing (RNS) as it is a press release detailing corporate activity, or potentially IP if we interpret 'IP' broadly to include the schedule of investor outreach. Given the nature of the content (listing dates/locations for investor conferences), it is a form of corporate communication that doesn't fit the specific report types (10-K, IR, ER). It is most similar to an announcement about investor engagement. I will select RNS as the most appropriate general regulatory/corporate announcement fallback, as it is a press release detailing corporate events, not the presentation material itself.
2017-10-04 French
Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for the period ending June 30, 2017. It contains a comprehensive set of financial statements, management discussion and analysis (Rapport semestriel d'activité), and an audit report (Rapport des commissaires aux comptes). It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2017
2017-09-22 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 21, 2017, announcing that Lysogene organized its first Parent Advisory Board meeting for children suffering from MPS IIIA. This type of announcement, detailing an event or consultation with stakeholders (parents) to gather input for clinical trial design, does not fit neatly into the standard financial filing categories like 10-K, ER, or IR. It is an announcement related to patient engagement and clinical strategy development. Since it is not a formal regulatory filing (like RNS), a specific report (like AR or IR), or a management/board change (MANG), the most appropriate classification is the general regulatory announcement/miscellaneous category, RNS, as it is a public communication about company activities that doesn't fit elsewhere, although it is closer to Investor Relations material. Given the options, RNS serves as the best fit for a general corporate press release detailing non-financial operational milestones.
2017-09-21 French
Communicated under the obligation to provide permanent information / Other communications
Environmental & Social Information Classification · 1% confidence The document is a press release dated September 21, 2017, announcing that Lysogene held its first Parent Advisory Board meeting for MPS IIIA. It details the purpose, participants (parents/caregivers), and outcomes of this advisory board, which provided input on therapy expectations and clinical trial design. This type of announcement, focusing on patient engagement, advisory boards, and feedback mechanisms related to drug development, does not fit neatly into standard financial filings like 10-K, ER, or IR. It is a specific operational/investor relations update. Since it is not a standard regulatory filing (like DIRS, DIV, or CAP) and is more specific than a general RNS, it is best classified as a general Investor Relations document or potentially a Regulatory Filing (RNS) if a more specific category is unavailable. Given the options, it is an announcement related to investor/patient relations and clinical strategy, which often falls under general regulatory announcements or investor communications. Since there is no specific category for 'Advisory Board Announcement' or 'Patient Engagement Update', and it is not a formal financial report, the most appropriate general category is Regulatory Filings (RNS) as a catch-all for non-standard announcements, or potentially Investor Presentation (IP) if it were a presentation, but it is a press release. Given the context of corporate communications that aren't strictly financial results or mandatory filings, RNS is the safest fallback, although it is a very specific type of press release. However, looking closely at the definitions, it is a specific corporate communication that doesn't match any other category well. It is not a formal report (10-K, IR), not a management change (MANG), not a dividend (DIV), not an earnings release (ER). It is a press release detailing an operational/patient relations event. RNS (Regulatory Filings) serves as the best general category for non-standard corporate announcements.
2017-09-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release dated September 12, 2017, announcing the creation of a new Clinical Advisory Board composed of internationally renowned experts. The content focuses on strategic advice for clinical development programs and commercialization plans for orphan drug candidates (MPS IIIA and GM1). This announcement concerns changes in the company's advisory structure and strategic direction, which aligns best with Board/Management Information (MANG), as it details the composition and role of a key advisory body reporting to management/the board, rather than a formal regulatory filing, financial report, or legal update. It is not a DEF 14A (Remuneration), DIRS (Director's Dealing), or a general RNS/RPA.
2017-09-12 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.